ERBB2 and neoplasm: While ILC is typically associated with both lower RS14–16 and poorer response to chemotherapy17,19, the trials that established that high RS is predictive of chemotherapy benefit in ER + HER2-negative BCA did not differentiate between tumor subtypes8,11,12, and no prospective trial has evaluated chemotherapy in ILC alone.